LWH-63

LWH-63 is a selective, non-peptidic antagonist of the corticotropin-releasing factor 1 receptor (CRF1R). It is primarily utilized as a pharmacological tool in preclinical research to investigate the neurobiological mechanisms underlying excessive alcohol consumption and the transition to alcohol dependence. Studies in rodent models have demonstrated that LWH-63 can significantly attenuate binge-like ethanol intake when administered systemically or via site-specific microinjections into the central nucleus of the amygdala (CeA). Notably, its inhibitory effects are specific to high-level, binge-like drinking and do not typically alter moderate or low-level ethanol consumption in non-dependent animals. This suggests that CRF1R signaling in the CeA is specifically recruited during episodes of excessive intake, making LWH-63 a valuable compound for studying the early stages of addiction and potential therapeutic targets for binge drinking.

Other names

4-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino-1-butanol